[HTML] nejm.org

[HTML][HTML] Pembrolizumab in microsatellite-instability–high advanced colorectal cancer

T André, KK Shiu, TW Kim, BV Jensen… - … England Journal of …, 2020 - Mass Medical Soc
Abstract Background Programmed death 1 (PD-1) blockade has clinical benefit in
microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after …
被引用次数：2018 相关文章

[引用][C] Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

T André, KK Shiu, TW Kim, BV Jensen… - New England Journal …, 2020 - cir.nii.ac.jp
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 …

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

KEYNOTE-177 Investigators - New England …, 2020 - researchinformation.amsterdamumc …
BACKGROUND Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-
instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy …

Pembrolizumab in microsatellite-instability-high advanced colorectal cancer

KEYNOTE-177 Investigators - New England Journal of …, 2020 - pure.johnshopkins.edu
BACKGROUND Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-
instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy …

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

T André, KK Shiu, TW Kim, BV Jensen, LH Jensen… - 2020 - pubmed.ncbi.nlm.nih.gov
Background Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-
instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy …

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

T André, KK Shiu, TW Kim, BV Jensen… - The New England …, 2020 - abdn.elsevierpure.com
Background: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-
instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy …
[PDF] kuleuven.be

[PDF][PDF] Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

T André, KK Shiu, TW Kim, BV Jensen, LH Jensen… - N Engl J …, 2020 - lirias.kuleuven.be
BACKGROUND Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-
instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy …

[引用][C] Pembrolizumab in microsatellite-instability-high advanced colorectal cancer

T André, KK Shiu, TW Kim… - New England …, 2020 - produccioncientifica.ucm.es
BACKGROUND Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-
instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy …
[PDF] uclouvain.be

[PDF][PDF] Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

T André, KK Shiu, TW Kim, BV Jensen, LH Jensen… - N Engl J …, 2020 - dial.uclouvain.be
BACKGROUND Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-
instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy …

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

T André, KK Shiu, TW Kim, BV Jensen… - The New England …, 2020 - europepmc.org
Background Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-
instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy …